FATE
Price
$1.21
Change
+$0.01 (+0.83%)
Updated
Jun 18 closing price
Capitalization
138.71M
40 days until earnings call
RXRX
Price
$5.11
Change
+$0.27 (+5.58%)
Updated
Jun 18 closing price
Capitalization
2.08B
53 days until earnings call
Interact to see
Advertisement

FATE vs RXRX

Header iconFATE vs RXRX Comparison
Open Charts FATE vs RXRXBanner chart's image
Fate Therapeutics
Price$1.21
Change+$0.01 (+0.83%)
Volume$1.86M
Capitalization138.71M
Recursion Pharmaceuticals
Price$5.11
Change+$0.27 (+5.58%)
Volume$35.11M
Capitalization2.08B
FATE vs RXRX Comparison Chart in %
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. RXRX commentary
Jun 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 20, 2025
Stock price -- (FATE: $1.21 vs. RXRX: $5.11)
Brand notoriety: FATE and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 90% vs. RXRX: 150%
Market capitalization -- FATE: $138.71M vs. RXRX: $2.08B
FATE [@Biotechnology] is valued at $138.71M. RXRX’s [@Biotechnology] market capitalization is $2.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both FATE and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -21.94% price change this week, while RXRX (@Biotechnology) price change was -5.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.

Reported Earning Dates

FATE is expected to report earnings on Jul 30, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.08B) has a higher market cap than FATE($139M). RXRX YTD gains are higher at: -24.408 vs. FATE (-26.667). FATE has higher annual earnings (EBITDA): -168.28M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. FATE (240M). FATE has less debt than RXRX: FATE (83.3M) vs RXRX (92.9M). RXRX has higher revenues than FATE: RXRX (59.8M) vs FATE (13.3M).
FATERXRXFATE / RXRX
Capitalization139M2.08B7%
EBITDA-168.28M-524.77M32%
Gain YTD-26.667-24.408109%
P/E RatioN/AN/A-
Revenue13.3M59.8M22%
Total Cash240M500M48%
Total Debt83.3M92.9M90%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATERXRX
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 17 days ago
85%
Bullish Trend 17 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRZYX20.190.04
+0.20%
T. Rowe Price Latin America Z
MEMSX8.460.01
+0.12%
Mercer Emerging Markets Equity I
CMLAX57.67-0.02
-0.03%
American Funds American Mutual 529A
CCASX70.02-0.02
-0.03%
Conestoga Small Cap Investors
CAABX25.07-0.01
-0.04%
ClearBridge Sustainability Leaders C

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CRBU. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+0.83%
CRBU - FATE
58%
Loosely correlated
+10.34%
ALLO - FATE
57%
Loosely correlated
-0.77%
RXRX - FATE
54%
Loosely correlated
+5.58%
CRSP - FATE
54%
Loosely correlated
+2.87%
CCCC - FATE
52%
Loosely correlated
-3.36%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+5.58%
CRSP - RXRX
72%
Closely correlated
+2.87%
BEAM - RXRX
63%
Loosely correlated
+1.92%
ABSI - RXRX
60%
Loosely correlated
+1.48%
ABCL - RXRX
58%
Loosely correlated
+11.22%
PRME - RXRX
57%
Loosely correlated
+11.46%
More